查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1827998

按产品类型、技术、应用和最终用户分類的动物生物技术市场—2025-2032 年全球预测

Animal Biotechnology Market by Product Type, Technology, Application, End-User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，动物生物技术市场将成长至 605.6 亿美元，复合年增长率为 8.71%。

主要市场统计数据
基准年2024年 310.4亿美元
预计2025年 338.1亿美元
预测年份：2032年 605.6亿美元
复合年增长率（%） 8.71%

动物生物技术的策略方向，以科学创新、监管演变和供应链弹性为商业决策的核心

动物生物技术正处于曲折点，分子工具、製造平台和法律规范的进步正在重新定义动物健康、营养和研发解决方案的开发和部署方式。该产业目前涵盖重组蛋白、疫苗创新、精准饲料添加剂和诊断技术，这些技术不仅支持畜牧业生产力，还支持生物医学研究和转化科学。投资者、政策制定者和企业领导者越来越关注具有韧性的价值链、更快的开发速度以及减少环境足迹并提升动物福利的技术。

基因编辑、高通量定序和先进细胞培养等开发能力正在赋能新型生技药品和平台技术，其下游影响可能延伸至治疗开发、诊断通量和农场层面的采用。同时，日益严格的公众监督、不断变化的贸易政策以及不断变化的采购惯例，迫使企业重新评估筹资策略和监管准备。本介绍概述了企业主管在整个动物生物技术生态系统中必须优先考虑的关键槓桿——技术、政策、供应链和商业策略，以便将科学机会转化为永续的竞争优势。

技术曲折点、不断发展的商业化模式和监管调整如何再形成动物生物技术的竞争动态

在平台技术日趋成熟和商业化路径不断发展的推动下，动物生物技术领域正在经历转型变革。基因编辑工具和转染方法正从概念验证使用案例，加速性状工程和疫苗抗原设计。同时，包括禽类、昆虫和哺乳动物平台在内的细胞培养系统的改进，透过减少对传统製程的依赖，实现了更具可扩展性、更具成本效益的生技药品生产。次世代定序和PCR工作流程的改进正在提高分析解析度并缩短获得结果的时间。

合约研发和製造机构正在扩展其提供端到端服务的能力，同时实验室与产业相关人员之间的伙伴关係也正在成为共用担风险和加速部署的常态。监管机构正在透过更迭代、基于科学的对话来适应新的模式，而永续性的压力正促使企业寻求更低排放的生产足迹和替代投入。这些转变正在共同改变竞争动态，并为能够整合平台技术、敏捷监管策略和弹性供应模式的组织开闢新的途径，从而抓住动物生物技术领域的新机会。

了解 2025 年关税变化如何重新调整整个动物生物技术价值链的供应链、筹资策略和营运风险框架

美国2025年关税政策的发展正在对动物生物技术领域的供应链经济、筹资策略和业务规划产生累积影响。试剂、实验室用具和专用零件的进口关税上调，推高了到岸投入成本，并挤压了製造商和服务提供者的净利率。企业正在透过加速供应商多元化、与非美国供应商签订长期合约以及探索近岸外包和回岸外包选项来应对关税波动的风险。这些变化对下游企业也产生了影响，包括采购週期、库存管理和资本配置决策。

关税引发的重组不仅会影响直接成本压力，还会影响战略伙伴关係和研发合作。先前依赖跨国贸易以取得早期研究资料的组织可能会转向国内供应商或扩大合作研究网络，以纳入地理位置分散的研究伙伴。监管合规和海关程序变得更加复杂，增加了跨境运输生技药品和诊断试剂套件的管理费用。因此，公司正在投资供应链可视性工具和双重筹资策略以保持连续性。同时，关税环境正在鼓励一些相关人员加快对本地製造能力的投资。这可以减少关税风险，但需要仔细考虑劳动力可用性、资本密集度和监管部门的核准。总体而言，关税格局可能促使风险框架和营运模式的重新调整，从而影响可预见的未来的策略规划。

详细的細項分析揭示了产品、技术、应用和最终用户的差异如何决定开发优先顺序、上市模式和投资重点

细分动态揭示了按产品类型、技术、应用和最终用户分類的价值创造路径和营运重点。按产品类型划分，该行业涵盖重组蛋白和疫苗。重组蛋白包括抗体、酵素和生长激素；酵素类别包括脂肪酶、植酸酶和蛋白酶；疫苗包括DNA疫苗、灭活疫苗、减毒活病毒疫苗和次单位疫苗。抗体优先考虑特异性和生产规模，酵素类强调耐热性和饲料整合，疫苗形式则需要与低温运输和监管方法协调。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • CRISPR/Cas9基因编辑技术的出现增强了家禽养殖的抗病能力
  • 商业规模的细胞培养肉生产，以减少环境影响并满足消费者需求
  • 整合人工智慧和基因组数据，实现乳牛群的预测性健康管理
  • 微生物组调节疗法在提升猪饲料效率和抗病能力的进展
  • 部署重组疫苗平台以控制畜牧业新出现的通用感染疾病

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第 8 章：动物生物技术市场（依产品类型）

  • 重组蛋白
    • 抗体
    • 酵素
      • 脂肪酶
      • 植酸酶
      • 蛋白酶
    • 生长激素
  • 疫苗
    • DNA疫苗
    • 灭活疫苗
    • 减毒活疫苗
    • 次单位疫苗

9. 动物生物技术市场（依技术）

  • 细胞培养
    • 禽类细胞培养
    • 昆虫细胞培养
    • 哺乳动物细胞培养
  • 基因工程
    • 基因编辑
    • 基因合成
    • 基因工程
  • PCR和DNA定序
    • 次世代定序
    • PCR套件
    • 桑格定序

第 10 章：动物生物技术市场（按应用）

  • 诊断
    • ELISA套件
    • 横向流动化验
    • PCR检测
  • 药物研发
    • 先导药物最适化
    • 临床前试验
    • 目标识别
  • 饲料添加剂
    • 碳水化合物降解酶
    • 植酸酶
    • 蛋白酶

第 11 章动物生物技术市场（依最终用户）

  • 动物农庄
  • 合约研究组织
  • 製药公司
  • 研究办公室

第 12 章：按地区分類的动物生物技术市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 13 章：动物生物技术市场（按类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 14 章：各国动物生物技术市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Zoetis Inc.
    • Merck & Co., Inc.
    • Elanco Animal Health Incorporated
    • Boehringer Ingelheim International GmbH
    • Ceva Sante Animale SA
    • Dechra Pharmaceuticals PLC
    • Vetoquinol SA
    • Phibro Animal Health Corporation
    • Virbac SA
    • IDEXX Laboratories, Inc.
Product Code: MRR-437517DB6EAD

The Animal Biotechnology Market is projected to grow by USD 60.56 billion at a CAGR of 8.71% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 31.04 billion
Estimated Year [2025] USD 33.81 billion
Forecast Year [2032] USD 60.56 billion
CAGR (%) 8.71%

A strategic orientation to animal biotechnology that frames scientific innovation, regulatory evolution, and supply chain resilience as core drivers of executive decision making

Animal biotechnology stands at an inflection point where advances in molecular tools, manufacturing platforms, and regulatory frameworks converge to redefine how animal health, nutrition, and research solutions are developed and deployed. The industry now spans recombinant proteins, vaccine innovation, precision feed additives, and diagnostics that support not only livestock productivity but also biomedical research and translational science. Investors, policy makers, and corporate leaders are increasingly focused on resilient value chains, accelerated development timelines, and technologies that reduce environmental footprint while enhancing animal welfare.

Emergent capabilities in gene editing, high-throughput sequencing, and advanced cell culture are enabling new classes of biologics and platform technologies whose downstream effects will extend across therapeutic development, diagnostic throughput, and farm-level adoption. At the same time, intensifying public scrutiny, evolving trade policies, and shifting procurement practices are prompting organizations to reassess sourcing strategies and regulatory readiness. This introduction frames the critical levers-technology, policy, supply chain, and commercial strategy-that executives must prioritize to convert scientific opportunity into sustainable competitive advantage across the animal biotechnology ecosystem.

How technological inflection points, evolving commercialization models, and regulatory adaptation are reshaping competitive dynamics in animal biotechnology

The landscape of animal biotechnology is undergoing transformative shifts driven by the maturation of platform technologies and evolving commercialization pathways. Gene editing tools and transgenic methodologies have moved from proof-of-concept stages to operational use cases that accelerate trait engineering and vaccine antigen design. Concurrently, improvements in cell culture systems-including avian, insect, and mammalian platforms-are enabling more scalable and cost-efficient biologics manufacturing that reduces dependence on legacy processes. These technological inflections are also complemented by advances in sequencing and diagnostics, where next-generation sequencing and improved PCR workflows are increasing analytic resolution and shortening time-to-result horizons.

Commercial models are also shifting: contract development and manufacturing organizations are expanding capabilities to offer end-to-end services, while partnerships between research laboratories and industry actors are becoming the norm to share risk and speed deployment. Regulatory authorities are adapting to new modalities with more iterative, science-based dialogues, while sustainability pressures are pushing firms to seek lower-emissions manufacturing footprints and alternative inputs. Together, these shifts are altering competitive dynamics and creating new pathways for organizations that can integrate platform technologies, agile regulatory strategies, and resilient supply models to capture emerging opportunities in animal biotechnology.

Understanding how 2025 tariff shifts are recalibrating supply chains, sourcing strategies, and operational risk frameworks across the animal biotechnology value chain

Tariff policy developments in the United States in 2025 are exerting cumulative effects on supply chain economics, sourcing strategies, and operational planning within the animal biotechnology sector. Increased import duties on reagents, laboratory equipment, and specialized components raise landed input costs and compress margins for manufacturers and service providers. Companies are responding by accelerating supplier diversification, securing longer-term contracts with non-U.S. vendors, and exploring near-shoring or reshoring options to mitigate exposure to tariff volatility. These changes have downstream implications for procurement cycles, inventory management, and capital allocation decisions.

Beyond immediate cost pressures, tariff-driven realignments influence strategic partnerships and R&D collaborations. Organizations that previously relied on cross-border exchanges for early-stage research materials may pivot toward domestic suppliers or broaden collaborative networks to include geographically diversified research partners. Regulatory compliance and customs processes have become more complex, increasing administrative overhead for cross-border shipments of biologics and diagnostic kits. As a result, firms are investing in supply chain visibility tools and dual-sourcing strategies to maintain continuity. In parallel, the tariff environment is prompting some stakeholders to accelerate investments in local manufacturing capacity, which can reduce tariff exposure but requires careful consideration of workforce availability, capital intensity, and regulatory approvals. Overall, the tariff landscape is driving a recalibration of risk frameworks and operational models that will influence strategic planning for the foreseeable future.

Detailed segmentation analysis revealing how product, technology, application, and end-user distinctions determine development priorities, go-to-market models, and investment focus

Segmentation dynamics reveal distinct pathways to value and operational priorities across product types, technologies, applications, and end users. Based on product type, the sector spans recombinant proteins and vaccines; recombinant proteins include antibodies, enzymes, and growth hormones, and the enzymes subset comprises lipases, phytases, and proteases, while vaccines encompass DNA vaccines, inactivated vaccines, live attenuated vaccines, and subunit vaccines. This diversity requires differentiated development strategies: antibodies prioritize specificity and manufacturing scale, enzymes emphasize thermostability and feed integration, and vaccine modalities demand tailored cold-chain and regulatory approaches.

Based on technology, the market includes cell culture, genetic engineering, and PCR and DNA sequencing; cell culture further breaks down into avian, insect, and mammalian cell culture, genetic engineering covers gene editing, gene synthesis, and transgenic technology, while PCR and DNA sequencing span next-generation sequencing, PCR kits, and Sanger sequencing. These technological axes shape capital intensity, talent requirements, and regulatory interfaces. Based on application, the landscape includes diagnostics, drug discovery, and feed additives; diagnostics subdivide into ELISA kits, lateral flow assays, and PCR-based tests, drug discovery covers lead optimization, preclinical testing, and target identification, and feed additives include carbohydrases, phytases, and proteases. Application-driven segmentation highlights where value accrues: diagnostics deliver recurrent consumable demand, drug discovery requires extended R&D investment, and feed additives emphasize agricultural integration. Based on end-user, demand is sourced from animal farms, contract research organizations, pharmaceutical companies, and research laboratories. Each end-user presents unique procurement patterns and service-level expectations, requiring vendors to align product design, regulatory support, and commercial models to end-user priorities and operational constraints.

Comparative regional intelligence demonstrating how Americas, Europe Middle East and Africa, and Asia-Pacific dynamics influence regulatory strategy, manufacturing, and adoption trajectories

Regional dynamics shape opportunity sets, regulatory contours, and adoption trajectories across the Americas, Europe Middle East and Africa, and Asia-Pacific. In the Americas, established research infrastructure and significant private investment foster rapid adoption of novel biologics and diagnostic platforms, while logistical hubs and advanced manufacturing clusters support contract development and manufacturing activity. North American regulatory dialogues increasingly emphasize harmonization and expedited pathways for innovative modalities, creating an environment where scale-up and commercial launch can proceed with greater predictability when regulatory strategies are proactively managed.

In Europe, the Middle East and Africa, regulatory diversity and complex cross-border trade arrangements require granular regulatory intelligence and adaptable supply chains. The region combines mature scientific centers with markets that are still developing capacity for advanced biologics, making partnerships and public-private initiatives particularly valuable. Policy priorities around animal welfare and sustainability often shape procurement preferences in this region. In the Asia-Pacific, a combination of rapid market growth, expanding domestic manufacturing capability, and increasing public research funding is accelerating adoption of vaccines, feed additives, and diagnostics. Local manufacturers and research institutions are scaling capabilities in cell culture and genetic engineering, and cross-border collaborations are common as firms leverage cost-competitive production while accessing large regional demand pools. Across all regions, firms that craft localized regulatory strategies and supply chain architectures will gain an edge in commercial execution.

How corporate strategies combining vertical integration, platform differentiation, and talent prioritization are determining competitive positioning in animal biotechnology

Company strategies in animal biotechnology are converging on several repeatable patterns that signal winners and pressure points across the competitive landscape. Leading actors are pursuing vertical integration and strategic partnerships to secure critical inputs, reduce time-to-market, and expand value-added service offerings. Contract development and manufacturing organizations are investing in platform flexibility to accommodate both recombinant proteins and vaccine modalities, enabling them to capture a broader share of outsourced development and production demand. At the same time, specialist technology providers are differentiating through proprietary cell lines, optimized fermentation processes, or unique sequencing and diagnostic chemistries that deliver performance advantages for specific end-users.

Investment profiles show a balance between R&D intensity for next-generation modalities and operational investments in scale, quality systems, and regulatory affairs. Talent acquisition and retention have emerged as key competitive factors, with companies prioritizing cross-disciplinary teams that combine molecular biology expertise with regulatory, manufacturing, and commercialization experience. Strategic M&A and licensing transactions are being used to access niche technologies or expand geographic reach, while alliances between academic institutions and commercial developers accelerate translational milestones. Overall, organizations that combine platform innovation with robust regulatory roadmaps and flexible manufacturing partnerships are best positioned to capture emerging opportunities across animal health, feed solutions, and diagnostic applications.

Actionable strategies for leaders to fortify supply chains, modularize manufacturing, engage regulators proactively, and accelerate platform-based innovation for commercial scalability

Industry leaders should adopt a suite of tangible actions to convert scientific capability into durable commercial advantage. First, diversify procurement and logistics by qualifying multiple suppliers across geographies, establishing strategic inventory buffers for critical reagents, and investing in supply chain visibility systems to anticipate disruptions. Second, prioritize modular manufacturing investments that allow rapid reconfiguration between recombinant proteins and vaccine production, reducing changeover time and maximizing capacity utilization. Third, commit to proactive regulatory engagement by participating in jurisdictional working groups, submitting pilot data packages early, and designing clinical and safety programs that align with evolving agency expectations.

Fourth, accelerate platform-based innovation by standardizing analytical methods, sharing validated cell lines or assay formats where permissible, and pursuing partnerships that co-fund translational milestones. Fifth, enhance commercial adoption through end-user education programs that demonstrate product efficacy, ease of use, and return on operational metrics for animal farms and research laboratories. Sixth, manage talent risk through targeted recruitment, professional development, and cross-functional governance that ensures continuity across R&D, manufacturing, and regulatory teams. Implementing these recommendations will enable organizations to mitigate near-term policy headwinds, optimize capital deployment, and build scalable operations aligned with long-term scientific and commercial objectives.

A multi-method research framework combining expert interviews, literature synthesis, patent and regulatory review, and data triangulation to ensure robust and actionable insights

This analysis is based on a multi-method research approach that integrates primary expert engagement, secondary literature synthesis, and structured data triangulation. Primary inputs included confidential interviews with senior R&D leaders, manufacturing executives, and regulatory specialists across academia, industry, and contract service providers; these interviews informed scenario development and validated emergent trends. Secondary research encompassed peer-reviewed literature, patent filings, regulatory guidance documents, and technical white papers to establish the scientific and regulatory context for technology adoption and manufacturing evolution.

Quantitative and qualitative findings were cross-checked through triangulation to reconcile divergent perspectives and to highlight consensus areas. The research process also included value-chain mapping exercises to identify critical bottlenecks in sourcing, production, and distribution, and a review of public procurement and policy developments to assess potential commercial implications. Quality assurance measures included independent peer review by domain experts, source transparency protocols, and iterative feedback loops with subject-matter specialists to ensure robustness and relevance of conclusions.

Executive conclusion summarizing how integrated scientific innovation, regulatory agility, and operational resilience will determine long-term success within animal biotechnology

In conclusion, animal biotechnology is evolving through an interplay of scientific innovation, supply chain realignment, and regulatory adaptation that together create both opportunity and complexity for market participants. Technological advances in cell culture, genetic engineering, and sequencing are unlocking new product classes and efficiencies, while tariff dynamics and regional policy shifts are forcing organizations to reassess sourcing, manufacturing, and partnership strategies. Successful players will be those that translate platform capabilities into reproducible manufacturing processes, maintain regulatory agility, and construct resilient supply networks that mitigate geopolitical and logistical risks.

Looking ahead, the ability to synthesize scientific rigor with operational excellence will determine which organizations capture sustained value. Firms that invest in modular manufacturing, cultivate diversified supplier ecosystems, and engage proactively with regulators will be better positioned to convert R&D breakthroughs into scalable products and services. The path forward requires a balance of innovation, disciplined execution, and strategic partnerships that together will drive long-term growth and impact across animal health, nutrition, and research domains.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of CRISPR/Cas9 gene editing to enhance disease resistance in poultry farming operations
  • 5.2. Commercial scale adoption of cell cultured meat production to reduce environmental impact and meet consumer demand
  • 5.3. Integration of artificial intelligence and genomics data for predictive health management in dairy cattle herds
  • 5.4. Advances in microbiome modulation therapies to improve feed efficiency and disease resilience in swine
  • 5.5. Deployment of recombinant vaccine platforms to control emerging zoonotic diseases in livestock industries

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Animal Biotechnology Market, by Product Type

  • 8.1. Recombinant Proteins
    • 8.1.1. Antibodies
    • 8.1.2. Enzymes
      • 8.1.2.1. Lipases
      • 8.1.2.2. Phytases
      • 8.1.2.3. Proteases
    • 8.1.3. Growth Hormones
  • 8.2. Vaccines
    • 8.2.1. DNA Vaccines
    • 8.2.2. Inactivated Vaccines
    • 8.2.3. Live Attenuated Vaccines
    • 8.2.4. Subunit Vaccines

9. Animal Biotechnology Market, by Technology

  • 9.1. Cell Culture
    • 9.1.1. Avian Cell Culture
    • 9.1.2. Insect Cell Culture
    • 9.1.3. Mammalian Cell Culture
  • 9.2. Genetic Engineering
    • 9.2.1. Gene Editing
    • 9.2.2. Gene Synthesis
    • 9.2.3. Transgenic Technology
  • 9.3. PCR And DNA Sequencing
    • 9.3.1. Next-Generation Sequencing
    • 9.3.2. PCR Kits
    • 9.3.3. Sanger Sequencing

10. Animal Biotechnology Market, by Application

  • 10.1. Diagnostics
    • 10.1.1. ELISA Kits
    • 10.1.2. Lateral Flow Assays
    • 10.1.3. PCR-Based Tests
  • 10.2. Drug Discovery
    • 10.2.1. Lead Optimization
    • 10.2.2. Preclinical Testing
    • 10.2.3. Target Identification
  • 10.3. Feed Additives
    • 10.3.1. Carbohydrases
    • 10.3.2. Phytases
    • 10.3.3. Proteases

11. Animal Biotechnology Market, by End-User

  • 11.1. Animal Farms
  • 11.2. Contract Research Organizations
  • 11.3. Pharmaceutical Companies
  • 11.4. Research Laboratories

12. Animal Biotechnology Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Animal Biotechnology Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Animal Biotechnology Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Zoetis Inc.
    • 15.3.2. Merck & Co., Inc.
    • 15.3.3. Elanco Animal Health Incorporated
    • 15.3.4. Boehringer Ingelheim International GmbH
    • 15.3.5. Ceva Sante Animale S.A.
    • 15.3.6. Dechra Pharmaceuticals PLC
    • 15.3.7. Vetoquinol S.A.
    • 15.3.8. Phibro Animal Health Corporation
    • 15.3.9. Virbac S.A.
    • 15.3.10. IDEXX Laboratories, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ANIMAL BIOTECHNOLOGY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ANIMAL BIOTECHNOLOGY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANIMAL BIOTECHNOLOGY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LIPASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LIPASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LIPASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LIPASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LIPASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LIPASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHYTASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHYTASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHYTASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHYTASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHYTASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHYTASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PROTEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PROTEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PROTEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PROTEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PROTEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PROTEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GROWTH HORMONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GROWTH HORMONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GROWTH HORMONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GROWTH HORMONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GROWTH HORMONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GROWTH HORMONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DNA VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DNA VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DNA VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DNA VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SUBUNIT VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SUBUNIT VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SUBUNIT VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SUBUNIT VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY AVIAN CELL CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY AVIAN CELL CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY AVIAN CELL CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY AVIAN CELL CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY AVIAN CELL CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY AVIAN CELL CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY INSECT CELL CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY INSECT CELL CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY INSECT CELL CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY INSECT CELL CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY INSECT CELL CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY INSECT CELL CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY MAMMALIAN CELL CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENE EDITING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENE EDITING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENE EDITING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENE EDITING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENE EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENE SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENE SYNTHESIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENE SYNTHESIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENE SYNTHESIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENE SYNTHESIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENE SYNTHESIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TRANSGENIC TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TRANSGENIC TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TRANSGENIC TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TRANSGENIC TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TRANSGENIC TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TRANSGENIC TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SANGER SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SANGER SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ELISA KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ELISA KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ELISA KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ELISA KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ELISA KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ELISA KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LATERAL FLOW ASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LATERAL FLOW ASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR-BASED TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR-BASED TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR-BASED TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR-BASED TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR-BASED TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR-BASED TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRECLINICAL TESTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRECLINICAL TESTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRECLINICAL TESTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRECLINICAL TESTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRECLINICAL TESTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRECLINICAL TESTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TARGET IDENTIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CARBOHYDRASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CARBOHYDRASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CARBOHYDRASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CARBOHYDRASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CARBOHYDRASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CARBOHYDRASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHYTASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHYTASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHYTASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHYTASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHYTASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHYTASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PROTEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PROTEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PROTEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PROTEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PROTEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PROTEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ANIMAL FARMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ANIMAL FARMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ANIMAL FARMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ANIMAL FARMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ANIMAL FARMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ANIMAL FARMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL ANIMAL BIOTECHNOLOGY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PCR AND DNA SEQUENCING, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 295. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2018-2024 (USD MILLION)
  • TABLE 296. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY, 2025-2032 (USD MILLION)
  • TABLE 297. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2018-2024 (USD MILLION)
  • TABLE 298. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY FEED ADDITIVES, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS ANIMAL BIOTECHNOLOGY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY RECOMBINANT PROTEINS, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY ENZYMES, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY VACCINES, 2025-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 312. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2018-2024 (USD MILLION)
  • TABLE 314. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY CELL CULTURE, 2025-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA ANIMAL BIOTECHNOLOGY MARKET SIZE, BY GENETIC ENGINEERING, 2018-2024 (USD M